Lion Point Capital’s Alder Biopharmaceuticals ALDR Stock Holding History

Lion Point Capital’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,204,600	Closed	-$22.7M	–	29
2019 Q3	$22.7M	Hold	1,204,600	–	–	2.53%	15
2019 Q2	$14.2M	Sell	1,204,600 -66,900	-5%	-$810K	1.4%	15
2019 Q1	$17.4M	Buy	1,271,500 +689,470	+118%	+$8.93M	1.57%	14
2018 Q4	$5.96M	Hold	582,030	–	–	0.94%	22
2018 Q3	$9.69M	Hold	582,030	–	–	0.91%	21
2018 Q2	$9.2M	Buy	+582,030	New	+$8.84M	0.83%	19

Lion Point Capital's ALDR Position: Q4 2019 in Review

Lion Point Capital sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,204,600 shares — an estimated $22.7M sold.

Lion Point Capital first reported a position in ALDR in Q2 2018 and held it in 6 quarters. The position peaked at $22.7M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Lion Point Capital reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Lion Point Capital sold 1,204,600 Alder Biopharmaceuticals shares in Q4 2019, an estimated $22.7M.
Lion Point Capital first reported a position in Alder Biopharmaceuticals in Q2 2018 and held it in 6 quarters.
Lion Point Capital's Alder Biopharmaceuticals position peaked at $22.7M in Q3 2019.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Lion Point Capital's 13F filing for Q4 2019, filed 14 Feb 2020.